Tuesday 15 December 2015

Becton, Dickinson and Company

Becton, Dickinson and Company
BDX(NYSE)

Sector:  Health Care
Beta Coefficient: 0.87
10 Yr Compound EPS Growth:  11.5%
10 Yr Compound DPS Growth 16.5%


Financial Result Year 2014

Revenues (m)   8,446
Net Income (m)  1,236
EPS  6.25
DPS 2.18
Cash flow per share 9.37
Current yield 1.7%

High Price  142.6  P/E 22.8   DY 1.53%
Low Price  105.2  P/E 16.8   DY  2.07%


Becton Dickinson is one of the premier medical supply and technology companies on the planet.

Becton Dickinson is a global health care company .  The company develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products through its three segments:

BD Medical  (54% of FY 2014 sales)
BD Diagnostics (14%)
and
BD Biosciences. (32%)


International sales account for about 59% of the total.

In mid-2014, the company announced the acquisition of CareFusion, a global provider of automated tools and systems designed to reduce patient medication errors and to prevent care-associated infections.

With the acquisition, while accretive, CareFusion may appear to dilute BD;s strong profit margins (NPM for BD is about 15% while CareFusion is about 11%), but it is anticipated synergies and growth to be a net positive.

Its dividend increases are not only steady but large, typically 10% per year, and the company plans to continue that pattern.  Dividend raises, last 10 years: 10 times.


Stock Performance Chart for Becton Dickinson and Co

No comments: